Market Place
Sourcing Support
A peak at Pfizer`s EZH2 inhibitor flashes hope for some
11 Sep 2022 //
FIERCEBIOTECH
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
13 Aug 2022 //
PRESS RELEASE
Epizyme Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Ipsen Extends Expiration Date of Tender Offer for Epizyme
04 Aug 2022 //
BUSINESSWIRE
Dire straits detailed for Epizyme before buyout by Ipsen
13 Jul 2022 //
FIERCEPHARMA
Ipsen snaps up Epizyme and cancer drug Tazverik for $247M
28 Jun 2022 //
FIERCEPHARMA
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study
02 Jun 2022 //
BUSINESSWIRE
Epizyme To Participate in H.C. Wainwright Global Investment Conference
17 May 2022 //
BUSINESSWIRE
Epizyme Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Epizyme Announces Date of First Quarter 2022 Financial Results
03 May 2022 //
BUSINESSWIRE
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Apr 2022 //
BUSINESSWIRE
Epizyme says Executive Appointment and Provides Tazemetostat Update
15 Mar 2022 //
BUSINESSWIRE
Epizyme to Participate in Upcoming Healthcare Conferences in March
02 Mar 2022 //
BUSINESSWIRE
Epizyme to trim workforce and pipeline in cost-cutting plan
02 Mar 2022 //
FIERCEBIOTECH
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
22 Feb 2022 //
PRESS RELEASE
GSK kills one of Barron’s early darlings, axing Epizyme pact
10 Feb 2022 //
FIERCEBIOTECH
Epizyme Announces Proposed Public Offering of Common Stock
26 Jan 2022 //
BUSINESSWIRE
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study
12 Dec 2021 //
BUSINESSWIRE
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on EZM0414
11 Dec 2021 //
BUSINESSWIRE
Epizyme Announces Updates to Its Board of Directors
18 Nov 2021 //
BUSINESSWIRE
Epizyme follicular lymphoma campaign showcases interactive coach
18 Nov 2021 //
FIERCEPHARMA
Epizyme rolls out rare blood cancer effort
16 Nov 2021 //
ENDPTS
Epizyme Reports Q3 2021 Financial Results and Provides Business Update
09 Nov 2021 //
BUSINESSWIRE
Epizyme Receives Fast Track USFDA& Announces Initiation of Ph1/1b Study
04 Nov 2021 //
BUSINESSWIRE
Epizyme Launches In My Blood Online Resource for People with Follicular Lymphoma
01 Nov 2021 //
BUSINESSWIRE
TAK1 blocker teams up with chemo to kill myeloma cells: study
18 Oct 2021 //
FIERCEBIOTECH
Epizyme Announces Data from TAZVERIK Clinical Programs to be Presented ESMO 2021
14 Sep 2021 //
BUSINESSWIRE
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Aug 2021 //
BUSINESSWIRE
Robert Bazemore makes Hutchmed deal his grand finale as Epizyme CEO
13 Aug 2021 //
ENDPTS
Epizyme and HUTCHMED Announce Strategic Collaboration
09 Aug 2021 //
BUSINESSWIRE
Epizyme Reports Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Epizyme Announces CEO Succession
09 Aug 2021 //
BUSINESSWIRE
Epizyme CEO Bazemore passes the baton for `next phase of growth`
09 Aug 2021 //
FIERCEBIOTECH
Epizyme Announces Date of Second Quarter 2021 Financial Results
04 Aug 2021 //
BUSINESSWIRE
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics
16 Jun 2021 //
BUSINESSWIRE
Epizyme Launches EZH2Now Testing for Relapsed/Refractory Follicular Lymphoma
15 Jun 2021 //
BUSINESSWIRE
Epizyme Announces Data to be Presented at Upcoming Medical Conferences in June
12 May 2021 //
BUSINESSWIRE
Epizyme`s EZH2 blocker boosts I-O in prostate cancer models
19 Apr 2021 //
FIERCEBIOTECH
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline
02 Mar 2021 //
BUSINESSWIRE
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline
02 Mar 2021 //
BUSINESSWIRE
Epizyme shouldn`t blame COVID-19 alone for sluggish launch
26 Feb 2021 //
FIERCEPHARMA
Epizyme Announces Expanded Loan Facility with Pharmakon for Additional $150 M
06 Nov 2020 //
BUSINESSWIRE
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK®
07 Oct 2020 //
BUSINESSWIRE
FDA Approvals Roundup: Tazverik, Crysvita, Xpovio
24 Jun 2020 //
RAPS
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK
18 Jun 2020 //
BUSINESS WIRE
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO
13 May 2020 //
BIOSPACE
Epizyme hires Kutok as CSO to find new uses for Tazverik
23 Mar 2020 //
FIERCE BIOTECH
AZ sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review
14 Feb 2020 //
ENDPTS
Epizyme Announces FDA Acceptance of NDA for Filing Priority Review for TAZVERIK
14 Feb 2020 //
BUSINESSWIRE
Risdiplam FIREFISH Study Demonstrated Significant Improvement in Infants
23 Jan 2020 //
PR NEWSWIRE
Tox issues? Check. Questionable efficacy data? Check. OK to market?
18 Dec 2019 //
ENDPTS
Epizyme’s sarcoma drug sails through FDA panel
18 Dec 2019 //
FIERCEPHARMA
FDA raises doubts about benefits of Epizyme`s cancer drug ahead of AdComm
18 Dec 2019 //
ENDPT NEWS
FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat
17 Dec 2019 //
ENDPTS
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat
02 Dec 2019 //
BUSINESS WIRE
